Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma

References

• Falk MH, Issels RD. Hyperthermia in oncology. Thresholds for thermal damage to normal tissues: An update. Int J Hyperthermia 2001;17:1–18
   PubMed Web of Science ®Google Scholar
• Cotte E, Passot G, Gilly FN, Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2010;2:31–5
   PubMed Web of Science ®Google Scholar
• Gori J, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, Felci N. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005;15:233–9
   PubMed Web of Science ®Google Scholar
• Rodt AP, Svarrer RO, Iversen LH. Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2013;11:232
   PubMedGoogle Scholar
• van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res 2003;23:1501–8
   PubMed Web of Science ®Google Scholar
• Duez A, Cotte E, Glehen O, Cotton F, Bakrin N. Appraisal of peritoneal cavity’s capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy. Surg Radiol Anat 2009;31:573–8
   PubMedGoogle Scholar
• Jones E, Alvarez Secord A, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, et al. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 2006;22:161–72
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Sasaki H, Kurokawa T, Kawahara K, Shukunami K, Katayama K, et al. Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: A long-term follow-up. Oncol Rep 2005;13:121–5
   PubMedGoogle Scholar
• Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 2009;14:683–94
   PubMed Web of Science ®Google Scholar
• Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–5
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1–11
   PubMedGoogle Scholar
• Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:1101–4
   PubMedGoogle Scholar
• Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235–41
   PubMed Web of Science ®Google Scholar
• Ceelen W, De Somer F, Van Nieuwenhove Y, Vande Putte D, Pattyn P. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin. Eur J Surg Oncol 2013;39:754–9
   PubMed Web of Science ®Google Scholar
• Yarmolenko PS, Moon EJ, Landon C, Manzoor A, Hochman DW, Viglianti BL, et al. Thresholds for thermal damage to normal tissues: An update. Int J Hyperthermia 2011;27:320–43
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998;69:103–8
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Marples M, Nelstrop AE. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054–7
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16
   PubMed Web of Science ®Google Scholar
• Raspe C, Piso P, Wiesenack C, Bucher M. Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 2012;25:348–55
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA, Abaid LN, Erwin MR, John CR, Micha JP, Brown JV III, et al. A retrospective review of the GelPort system in single-port access pelvic surgery. J Minim Invasive Gynecol 2009;16:743–7
   PubMedGoogle Scholar
• Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56
   PubMed Web of Science ®Google Scholar
• González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2010;2:68–75
   PubMed Web of Science ®Google Scholar
• Cohen JD, Robins HI. Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia in vitro. Cancer Res 1987;47:4335–437
   PubMed Web of Science ®Google Scholar
• Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, et al. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 1991;51:2994–3000
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Maehara Y, Baba H, Takahashi I, Kusumoto H, Ohno S, et al. Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. Br J Cancer 1993;68:259–63
   PubMedGoogle Scholar
• Herman TS1, Teicher BA, Chan V, Collins LS, Abrams MJ. Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Phys 1989;16:443–9
   PubMed Web of Science ®Google Scholar
• Mahteme H, Wallin I, Glimelius B, Påhlman L, Ehrsson H, Ozols RF, et al. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol 2008;64:907–11
   PubMed Web of Science ®Google Scholar
• Haugk M, Testori C, Sterz F, Uranitsch M, Holzer M, Behringer W, et al. Relationship between time to target temperature and outcome in patients treated with therapeutic hypothermia after cardiac arrest. Crit Care 2011;15:R101
   Web of Science ®Google Scholar